Xenoport, Inc. (XNPT)
-NasdaqGS 6.75 
0.28(4.33%) May 17, 4:00PM EDT|After Hours
:
6.75 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 6.47 |
|---|
| Open: | 6.61 |
|---|
| Bid: | 6.43 x 100 |
|---|
| Ask: | 7.63 x 300 |
|---|
| 1y Target Est: | 11.00 |
|---|
| Beta: | 0.63 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 6.51 - 6.83 |
|---|
| 52wk Range: | 5.00 - 12.98 |
|---|
| Volume: | 487,478 |
|---|
| Avg Vol (3m): | 408,300 |
|---|
| Market Cap: | 319.96M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- XenoPort: Horizant likely available in early JuneAP(Fri, May 17)
- XenoPort Provides Update on Availability of HorizantBusiness Wire(Fri, May 17)
- XENOPORT INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 15)
- XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and ExhibitEDGAR Online(Mon, May 6)
- XenoPort Announces New Employment Inducement AwardsBusiness Wire(Fri, May 3)
- Biotech Stock Value Fundamentally Based on Individual Drug Development and the Competing Landscape: Expert Analyst Boris Peaker Discusses His Coverage of the Biotechnology Sector with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
- XENOPORT INC FinancialsEDGAR Online Financials(Tue, Apr 30)
- XenoPort Is Now Oversold (XNPT)at TheStreet(Fri, Apr 26)
- Loss Widens at XenoPortZacks(Thu, Apr 25)
- XenoPort's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Apr 24)
- Xenoport Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, Apr 24)
- XenoPort Reports First Quarter Financial ResultsBusiness Wire(Wed, Apr 24)
- XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 24)
- Q1 2013 XenoPort, Inc. Earnings Release - After Market CloseCCBN(Wed, Apr 24)
- XenoPort: A High Probablity Run-Up Tradeat Seeking Alpha(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 26.20 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.14 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.55 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | -0.60 |
|---|
Business Summary
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders.
View More